Erythroid Response to Treatment in 50 Evaluable Patients
| MDS Subtype . | No. . | NR . | PR . | CR . | All R . | % R . |
|---|---|---|---|---|---|---|
| RA | 10 | 8 | 1 | 1 | 2 | 20* |
| RARS | 13 | 7 | 1 | 5 | 6 | 46* |
| RAEB | 27 | 17 | 6 | 4 | 10 | 37* |
| All patients | 50 | 32 | 8 | 10 | 18 | 38 |
| MDS Subtype . | No. . | NR . | PR . | CR . | All R . | % R . |
|---|---|---|---|---|---|---|
| RA | 10 | 8 | 1 | 1 | 2 | 20* |
| RARS | 13 | 7 | 1 | 5 | 6 | 46* |
| RAEB | 27 | 17 | 6 | 4 | 10 | 37* |
| All patients | 50 | 32 | 8 | 10 | 18 | 38 |
Note that three patients (all nonresponders) only were evaluable to treatment with epo alone.
Abbreviations: NR, no response; PR, partial response; CR, complete response.
No statistically significant differences in response rate (χ2 analysis, P = .43).